Gå direkt till innehåll

Senaste nyheterna

Lokon Pharma Initiates a Collaboration with Affibody to Develop Novel Cancer Therapeutics

Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB to develop a novel therapeutic strategy to treat cancer.
“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already h

Lokon Pharma develops cutting edge cancer immunotherapeutics

Lokon Pharma AB is a Swedish biotech company developing the LOAd platform of oncolytic adenoviruses genetically engineered to express immunostimulatory genes in malignant tumors and tumor stroma.

Lokon Pharma AB
Bredgränd 14
753 20 Uppsala
Sverige